Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

Blood

Volumn 109, Issue 10, 2007, Pages 4586-4588

  Armand, Philippe ^a   Kim, Haesook T ^a   Cutler, Corey S ^a   Ho, Vincent T ^a   Koreth, John ^a   Alyea, Edwin P ^a   Soiffer, Robert J ^a   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; FERRITIN; METHOTREXATE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHELATION THERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FERRITIN BLOOD LEVEL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERFERRITINEMIA; IRON OVERLOAD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; THALASSEMIA; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 34248383686     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-054924     Document Type: Article

References (18)

1. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417-421.
2. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329:840-844.
3. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in adult thalassemia. Blood. 1992;80:1603-1607.
4. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87:2082-2088.
5. Kamble R, Mims M. Iron-overload in long-term survivors of hematopoietic transplantation. Bone Marrow Transplant. 2006;37:805-806.
6. Butt NM, Clark RE. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant. 2003;32:909-913.
7. Lichtman SM, Attivissimo L, Goldman IS, Schuster MW, Buchbinder A. Secondary hemochromatosis as a long-term complication of the treatment of hematologic malignancies. Am J Hematol. 1999;61:262-264.
8. Kornreich L, Horev G, Yaniv I, Stein J, Grunebaum M, Zaizov R. Iron overload following bone marrow transplantation in children: MR findings. Pediatr Radiol. 1997;27:869-872.
9. Ho GT, Parker A, MacKenzie JF, Morris AJ, Stanley AJ. Abnormal liver function tests following bone marrow transplantation: aetiology and role of liver biopsy. Eur J Gastroenterol Hepatol. 2004;16:157-162.
10. Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematol. 2000;4:505-512.
11. Kallianpur AR, Hall LD, Yadav M, et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:1155-1164.
12. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006;37:857-864.
13. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:987-989.
14. Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047-1055.
15. Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol. 2001;38:37-56.
16. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417-423.
17. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574-578.
18. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Amer Stat Assoc. 1999;94:496-509.